Selected Publications

1.      Jing, W*., ……., Lu, H*., & Gao, Y*. (2025). Gut Microbiota-associated Metabolites Affected the Susceptibility to Heart Health Abnormality in Young Migrants at High-altitude. Exploration, https://doi.org/10.1002/EXP.20240332 (*Corresponding Author) (Q1 Top, Live IF 22.5)

2.      Jing, W*., ……., Lu, H*., & Wang, S*. (2025). Gut microbiota-derived tryptophan metabolites regulated by Wuji Wan administration to attenuate the colitis through AhR signaling activation. Acta Pharmaceutica Sinica B, https://doi.org/10.1016/j.apsb.2024.11.009 (*Corresponding Author) (Q1 Top, IF 14.6)

3.      Wang, Y., ……. Lu, H*., Zhou, W*., Gao, Y*.  (2025). Plasma Proteomic Profiling Reveals ITGA2B as A Key Regulator of Heart Health in High-altitude Settlers, Genomics, Proteomics & Bioinformatics, 2025, https://doi.org/10.1093/gpbjnl/qzaf030 (*Corresponding Author) (Q1 Top, IF 11.5)

4.      Liu, J., ......Lu, H*.and Yao, L*. (2025). Rhodiola crenulata extract inhibits cell pyroptosis to ameliorate pulmonary vascular remodeling in rats through the regulation of decadienylcarnitine/NLRP3/GSDMD axis. Journal of Ethnopharmacology, 254, 120439(*Corresponding Author) (Q1 TOP, IF 5.4)

5.      Luo, X., …… Lv, H*., and Ju, Y*. (2025). Development of a liquid chromatography-mass spectrometry based targeted metabolomics method for discovering diagnostic biomarkers in Kawasaki disease. J Chromatography A., 1741, 465619. (*Corresponding Author) (Q1 TOP, IF 3.8)

6.      Gu, T., ......, Lu, H*., Tang, H*., Li, H*.and  Liu, Z*. (2025). Temporal changes of hepatic drug-metabolizing enzymes mediated by hepatic ischemia-reperfusion injury and the protective effect of Oridonin. Scientific Reports, 15, 28552. (*Corresponding Author) (Q1, IF 3.9)

7.      Liu, J., ……Han, Z*., Fang, H*., and Lu, H*. (2024). Integrating artificial intelligence with Mass spectrometry-driven molecular Profiling Methods to advance the diagnosis and therapy for infectious diseases. Pharmacology & Therapeutics, 263, 108712 (*Corresponding Author) (Q1 Top, IF 12.5)

8.      Bao, C., …… Chen, L*., Lv, H*., & Fang, H*. (2024). A cross-disease, pleiotropy-driven approach for therapeutic target prioritization and evaluation. Cell Reports Methods, 4(4), 100757 (*Corresponding Author) (Q1 Top, IF 4.3)

9.      Fu, M., …… Lu, H*., and Yao, L*. (2024). Zhishi Xiebai Guizhi Decoction modulates hypoxia and lipid toxicity to alleviate pulmonary vascular remodeling of pulmonary hypertension in rats. Chin Med., 1, 173. (*Corresponding Author) (Q1, IF 5.7)

10.   Liu, J., Jing, Wang., Wang, T., Hu, Z., and Lu, H*. (2023). Functional metabolomics revealed the dual-activation of cAMP-AMP axis is a novel therapeutic target of pancreatic cancer. Pharmacological Research, 187, 106554 (*Corresponding Author) (Q1 TOP, IF 10.5)

11.   Wang, T., Hu, L., …..Liu, J., Xia, H. and Lu, H*. (2022). Functional metabolomics defined metabolic-characteristics of chronic hepatitis that is significantly differentiated from acute hepatitis. Pharmacological Research, 180, 106248 (*Corresponding Author) (Q1 TOP, IF 10.5)

12.   Wang, T., Guo, R., Hu, L., Liu, J. and Lu, H*. (2022). Mass Spectrometry-Based Targeted Metabolomics Revealed the Regulatory Roles of Magnesium on Biofilm Formation in Escherichia coli by Targeting Functional Metabolites. Journal of Analysis and Testing, 6, 89–97. (*Corresponding Author) (Q1 TOP, IF 5.5)

13.   Dong, S., Zhu, M.,...Hu, L., Jing, W*., Lu, H*. and Wang, S., etc (2021). Dihydromyricetin improves DSS-induced colitis in mice via modulation of fecal-bacteria-related bile acid metabolism. Pharmacological Research, 171, 105767. (*Corresponding Author) (Q1 TOP, IF 10.5)

14.   Wang, T., Liu, J., Luo, X., Hu, L., and Lu, H*. (2021). Functional metabolomics innovates therapeutic discovery of traditional Chinese medicine derived functional compounds. Pharmacology & Therapeutics, 224, 107824. (*Corresponding Author). (Q1 TOP, IF 12.5)

15.   Jing, W., Luo, X., and Lu, H*., et al. (2021). Berberine improved the colitis in rats by the regulation of microbial tryptophan metabolites to activate AhR. Pharmacological Research, 164, 105358. (*Corresponding Author) (Q1 TOP, IF 10.5)

16.   Guo, R., Luo, X., Liu, J., and Lu, H*. (2021). Mass spectrometry based targeted metabolomics precisely characterized new functional metabolites that regulate biofilm formation in Escherichia coli. Analytica Chimica Acta, 1145, 26-36. (*Corresponding Author) (Q1 TOP, IF 6.5)

17.   Liu, J., Luo, X., Guo, R. and Lu, H*. (2020). Cell metabolomics reveals berberine inhibited cell viability and metastasis in pancreatic cancer cells by regulating citrate metabolism. Journal of Proteome Research, 19: 3825-3836 (*Corresponding Author) (Q1, IF 5.37)

18.   Luo, X., Liu, J., Lu, H*., etc. (2020). Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis. Pharmacological Research, 156, 104805. (*Corresponding Author) (Q1 TOP, IF 10.5)

19.   Guo, R., Luo, X., Liu, J., Lu, H*., etc. (2020). Multi-omics strategies decipher therapeutic discovery of traditional Chinese medicine. Pharmacological Research, 19, 3825–3836. (*Corresponding Author) (Q1 TOP, IF 10.5)

20.   Guo R., Lu H*. (2020). Targeted Metabolomics Revealed the Regulatory Role of Manganese On Small-Molecule Metabolism of Biofilm Formation in Escherichia Coli. Journal of Analysis and Testing, 4, 226–237. (*Corresponding Author) (Q1 TOP, IF 7.0)

21.   Hu, L., Liu, J., Zhang, W., Wang, T., H, Lu*., etc. (2020). Functional metabolomics decipher biochemical functions and associated mechanisms underlie small-molecule metabolism. Mass Spectrometry Reviews, 39, 417–433 (*Corresponding Author) (Q1 TOP, IF 9.0)

22.   Xu, G., Guo, H., and Lv, H*. (2019). Metabolomics Assay Identified a Novel Virulence-Associated Siderophore Encoded by the High-Pathogenicity Island in Uropathogenic Escherichia coli. J Proteome Res., 18, 2331-2336. (*Corresponding Author) (Q1, IF 5.37)

23.   Luo, X., Guo, R., Xu, X., Li, X., Lu, H*., etc. (2019). Mass Spectrometry and Associated Technologies Delineate The Advantageously Biomedical Capacity Of Siderophores In Different Pathogenic Contexts. Mass Spectrometry Reviews, 38, 239-252 (*Corresponding Author) (Q1 TOP, IF 9.0)

24.   Su, Q, Xu, G. Guan, T. Que, Y. and Lu, H*. (2018). Mass spectrometry-derived systems biology technologies delineate the system’s applications of siderophores with chemistry and biology. Mass Spectrometry Reviews, 37, 188-201(Invited by Editor in Chief) (*Corresponding Author) (Q1 TOP, IF 9.0)

25.   Su, Q., Guan, T. B., He, Y. and Lv, H*. (2016). Siderophore biosynthesis governs the virulence of uropathogenic Escherichia coli by coordinately modulating the differential metabolism. Journal of Proteome Research, 15, 1323–1332. (*Corresponding Author) (Q1, IF 5.37)

26.   Nie, W.N., Yan, L. Y. Lee, Y. H., Guha, C., Kurland, I. J., and Lu, H.T.,* (2016).Advanced mass spectrometry based multiple omics technologies for exploring the pathogenesis of hepatocellular carcinoma. Mass Spectrometry Reviews, 35, 331-349. (*Corresponding Author) (Q1 TOP, IF 9.0)

27.   Lv, H. T*., Hung, C. S., and Henderson, J. P.* (2014): Metabolomic Analysis of Siderophore Cheater Mutants Reveals Metabolic Costs of Expression in Uropathogenic Escherichia coli. Journal of Proteome Research, 13, 1397-1404. (*Corresponding Author) (Q1, IF 5.37)

28.   Lv, H. T.* (2013): Mass spectrometry based metabolomics towards understanding of gene functions with a diversity of biological contexts, Mass Spectrometry Reviews, 32, 118-128. (*Corresponding Author) (Q1 TOP, IF 9.0)

29.   Lv, H.T., and Henderson, J. P. (2011): Yersinia High Pathogenicity Island genes modify the Escherichia coli primary metabolome independently of siderophore production. Journal Proteome Research, 10, 5547–5554. (Q1, IF 5.37)

30.   Lv, H.T., Palacios, G., Hartil, K. and Kurland, I.J. (2011): Advantages of Tandem LC-MS for the Rapid Assessment of Tissue-specific Metabolic Complexity using a Pentafluorophenylpropyl Stationary Phase. Journal Proteome Research, 10, 2104-2012. (Q1, IF 5.37)

31.   Lv, H.T*., Hung, C. S., Chaturvedi, K. S., Hooton, T. M., and Henderson, J.P.* (2011): Development of an integrated metabolomic approach for Infectious Diseases Research. Analyst, 136, 4752-4763. (*Corresponding Author) (Q1, IF 5.2)

32.   Yan, L. Y., Nie, W. N., and Lv, H. T. * (2015) Metabolic Phenotyping of the Yersinia High-Pathogenicity Island that Regulates Central Carbon Metabolism. Analyst, 140, 3356-3361. (*Corresponding Author) (Q1, IF 5.2)

33.   Lv, H.T*., Liu, L., Palacios, G. and Chen, X. (2011): Metabolomic Analysis Characterizes Tissue Specific Metabolic Perturbations of the Rats Induced by Indomethacin. Analyst, 136, 2260-2269. (*Corresponding Author) (Q1, IF 5.2)